Background
==========

Comparing different interventions for the same condition is often difficult. Large direct comparisons are uncommon, and usually represent only a fraction of the total randomised trial data available. Instead we often have large numbers of randomised trials comparing different interventions with the same or similar comparators, like placebo or an active comparator. These may be direct comparisons, but not the direct comparisons we want.

Indirect comparison of interventions using a common comparator is a valuable alternative because it uses more of the published data \[[@B1]\], and has been done before for analgesics in acute pain \[[@B2]\] and migraine treatments \[[@B3]\]. Even this approach can be devalued because clinical trials in published papers are not consistent in the outcomes they report, or the way they report them \[[@B4]\].

The ideal should be to compare interventions of equivalent intensities or dose, in the same condition, at similar disease severity, using the same outcomes properly reported, over the same period of time. In this study we use the example of published studies of phosphodiesterase-5 (PDE-5) inhibitors for male erectile dysfunction to examine the problems of comparing therapies. PDE-5 inhibitors were chosen because they have been introduced within the past decade, by three different pharmaceutical companies, and in an era of good clinical trial practice. There are no good quality trials directly comparing PDE-5 inhibitors at equivalent doses.

Methods
=======

We sought randomised trials of three PDE-5 inhibitors (sildenafil, tadalafil, vardenafil), with placebo or active comparator, in men with erectile dysfunction of any causation. Previous systematic reviews \[[@B5]-[@B9]\] were used to source trials or trial data, supplemented by electronic searches of PubMed (to June 2005) and the Cochrane Library (issue 1, 2005) using drug names and randomis(z)ed trial.

For inclusion a trial had to be randomised and double blind, use one of the three oral PDE-5 inhibitors in men with erectile dysfunction, be conducted in the home setting, last three weeks or longer, have a minimum of 10 men per group, and report useful information on efficacy or adverse events. Abstracts were read, and potentially useful reports retrieved in full paper copy. Decisions on inclusion or exclusion were made by consensus. No information was taken from posters or abstracts, and studies were read carefully to avoid including duplicate material. Studies were scored for reporting quality using a common method \[[@B10]\] utilising reporting of randomisation, blinding and withdrawals. The maximum score possible was 5 points, and no study could be included with fewer than 2 points.

Information extracted from studies included the number of men studied, the cause of erectile dysfunction, and country where the study was performed. Any type of outcome was initially extracted from the studies, in continuous or dichotomous form, and with any dispersion information available. Outcomes could be reported in tables, in graphs, or in text. The following outcomes were sought particularly:

Efficacy
--------

• Improved erections (\"Has the treatment you have been taking over the past four weeks improved your erections?\")

• Erections per week

• Successful attempts at sexual intercourse

• More than 60% or 75% successful

• More than 40% successful

• Final score or change from baseline on question 3 of the International Index of Erectile Function (IIEF) \[[@B11]\] (\"Over the past four weeks, when you attempted sexual intercourse, how often were you able to penetrate your partner?\")

• Final score or change from baseline on question 4 of the IIEF (\"Over the past four weeks, during sexual intercourse, how often were you able to maintain your erection after you had penetrated your partner?\")

• Final score or change from baseline on the IIEF erectile function domain score

• Normal erectile function at end of study (IIEF total score of 22 or more out of 30)

Withdrawal
----------

• All cause

• Lack of efficacy

• Adverse event

Adverse events
--------------

• Patient with at least one adverse event

• Severe (using standard adverse event definitions)

• Serious (using standard adverse event definitions)

• Treatment-related

• Headache

• Dyspepsia

• Flushing

• Nasal congestion or rhinitis

• Visual disturbance

• Myalgia and/or back pain

• Other individual adverse events

Other information sought from trials was the relationship between taking a dose of PDE-5 inhibitor and time of attempted or successful sexual intercourse. The aim was to examine evidence for differences between speed of onset or duration of effect.

Guidelines for quality of reporting of meta-analyses were followed where appropriate \[[@B12]\]. The prior intention was to pool data where there was clinical homogeneity, with similar patients, dose, duration, outcomes, and comparators, but not where numbers of events were small, and random chance could dominate effects of treatment \[[@B13]\].

Clinical trials of PDE-5 inhibitors use both fixed dosing and dose optimisation, in which doses can be increased or decreased within set levels to balance improved efficacy with adverse events. We noted that most dose optimisation schedule studies reported that the majority of patients were on the top dose at the end of the study. We therefore chose to include dose optimisation trials with trials of the top fixed dose. We analysed only licensed doses, as listed in the British National Formulary.

Our intent was to minimise subgroup analysis. There was little prior information that erectile dysfunction from particular causes responds differently to treatment. We used the intention to treat definitions used in the studies (usually number of patients randomised, receiving at least one dose of trial drug, and with at least one post randomisation measurement). When that information was not available we used the numbers of men used as denominators in the trial reports.

Mean results for continuous data were calculated and weighted by the number of men in treatment groups. Homogeneity tests and funnel plots, though commonly used in meta-analysis, were not used here because they have been found to be unreliable \[[@B14]-[@B16]\]. Instead clinical homogeneity was examined graphically \[[@B17]\]. Relative benefit (or risk) and number-needed-to-treat (or harm) were calculated with 95% confidence intervals. Relative risk was calculated using a fixed effects model \[[@B18]\], with no statistically significant difference between treatments assumed when the 95% confidence intervals included unity. We added 0.5 to treatment and comparator arms of trials in which at least one arm had no events. Number-needed-to-treat (or harm) was calculated by the method of Cook and Sackett \[[@B19]\] using the pooled number of observations only when there was a statistically significant difference of relative benefit or risk (where the confidence interval did not include 1).

The following terms were used to describe outcomes in terms of benefit, harm or prevention of harm:

• When significantly more beneficial events occurred with PDE-5 inhibitor than with placebo we used the term the number-needed-to-treat to produce one event (NNT).

• When significantly fewer withdrawals or adverse events occurred with PDE-5 inhibitor than with placebo we used the term the number-needed-to-treat to prevent one event (NNTp).

• When significantly more adverse events occurred with PDE-5 inhibitor compared with placebo we used the term the number-needed-to-harm to cause one event (NNH).

The format for presentation of trial details and results was decided prospectively, to show the number of trials and patients on which calculations were based, and either the number of events, or event rates, together with relative risk or benefit and NNT. In this way absolute as well as relative differences would be apparent. Summary data would be shown only where it was from two or more studies, with more than 200 patients, and more than 30 events. No formal testing of difference was planned.

Results
=======

There were 35 included studies using sildenafil \[[@B20]-[@B54]\], treating 7135 men with a mixture of conditions causing erectile dysfunction (Table [1](#T1){ref-type="table"}); one study \[[@B40]\] was analysed as two trials. Of the men, 3279 received placebo and 3856 sildenafil, of whom all but 90 took licensed doses of 25 to 100 mg. Optimised dosing with 25--100 mg was most used (2546 men), followed by 100 mg (506) or 50 mg (370). All were placebo-controlled with no active comparator. Quality scores were high, 11 trials scoring 5 of 5 points, 17 scoring 4 points, six 3 points, and two 2 points. One further study \[[@B55]\] used a withdrawal model after successful treatment, and information from the 205 men in this study was not included in this analysis.

###### 

PDE-5 inhibitor trials by condition (percent of total)

  **Condition**                      **Sildenafil**   **Tadalafil**   **Vardenafil**
  ---------------------------------- ---------------- --------------- ----------------
  Mixed aetiology                    67               75              73
  Diabetes                           14               11              13
  Prostatectomy                      0.0              15              13
  Depression                         5.7              0.0             0.0
  Spinal cord injury                 5.3              0.0             0.0
  Multiple sclerosis                 3.1              0.0             0.0
  Coronary heart disease             2.1              0.0             0.0
  Radiotherapy for prostate cancer   1.7              0.0             0.0
  Renal failure and haemodialysis    1.0              0.0             0.0
  Rectal surgery                     0.5              0.0             0.0
  Spina bifida                       0.5              0.0             0.0

There were eight included studies using tadalafil \[[@B56]-[@B63]\], treating 2071 men with a mixture of conditions causing erectile dysfunction (Table [1](#T1){ref-type="table"}). Of these, 632 received placebo and 1439 tadalafil, of whom all but 35 took licensed doses of 5 to 20 mg. All were placebo-controlled with no active comparator. Doses of 20 mg (1258) or 10 mg (109) were most frequent, with no dose-optimised studies. Quality scores were high, two trials scoring 5 of 5 points, one scoring 4 points, four 3 points, and one 2 points. One further trial \[[@B64]\] was a population dose-response study and was not included.

There were seven included studies with vardenafil \[[@B65]-[@B71]\], treating 3374 men with a mixture of conditions causing erectile dysfunction (Table [1](#T1){ref-type="table"}). Of these, 1067 received placebo and 2307 vardenafil, all at licensed doses of 5 to 20 mg. Fixed dosing was most used with 10 mg (809) or 20 mg (698), together with some dose optimised studies of 5--20 mg (382). All were placebo-controlled with no active comparator. Quality scores were high, three trials scoring 5 of 5 points, and four scoring 4 points. One further trial \[[@B72]\] had no placebo group and enriched enrolment and was not included.

Details of the included studies are in additional files 1: conditions, country, treatment, dose, duration and quality score \[see [Additional file 1](#S1){ref-type="supplementary-material"}\]; 2: efficacy outcomes, withdrawals, and adverse events (patients with any adverse event, and severe, serious and treatment-related adverse events) \[see [Additional file 2](#S2){ref-type="supplementary-material"}\]; and 3: details of particular adverse events \[see [Additional file 3](#S3){ref-type="supplementary-material"}\].

Study reporting
===============

All studies provided background information on participants. Typically men had to have a history of erectile dysfunction of at least three to six months, and the average age of men was generally in the mid 50s or older. Some studies had an enriched enrolment in which previous unsuccessful treatment with a PDE-5 inhibitor was an exclusion criterion. This applied to five of eight tadalafil studies, and six of seven vardenafil studies \[see [Additional file 1](#S1){ref-type="supplementary-material"}\], but none of the sildenafil studies. One vardenafil study \[[@B70]\] included only men previously unresponsive to sildenafil.

Studies almost always documented that PDE-5 inhibitor was to be taken as needed to a maximum of one treatment a day, with the additional instruction for sildenafil and vardenafil that the dose be taken about an hour before intercourse. Some studies gave information on the number of doses actually taken. Many of the dose optimised studies reported the proportion of men on maximum dose at the end of the study, which was always over 50%, and typically 60--80%. Trial duration was typically four to 12 weeks, with 12 weeks the commonest duration.

A number of different conditions causing erectile dysfunction were studied (Table [1](#T1){ref-type="table"}). All three PDE-5 inhibitors had a similar proportion of men with mixed aetiology (organic, psychogenic, or mixed) and diabetes. Erectile dysfunction after prostatectomy was studied for tadalafil and vardenafil, but not sildenafil; none of a number of studies of sildenafil after prostatectomy could be included, mainly because they were not randomised. With sildenafil, a variety of additional conditions were studied, including depression, spinal cord injuries, multiple sclerosis, coronary heart disease, radiotherapy for prostate cancer, renal failure and haemodialysis patients, rectal surgery and spina bifida.

Many studies were multicentre, often performed in different countries (Table [2](#T2){ref-type="table"}). Europe, North America and Australia accounted for most of the men in the studies for tadalafil and vardenafil. Sildenafil studies in addition were reported from South America, Asia, and Africa.

###### 

Patient numbers in PDE-5 inhibitor trials (by world region)

  **Region**                 **Sildenafil**   **Tadalafil**   **Vardenafil**
  -------------------------- ---------------- --------------- ----------------
  Europe                     2040             839             309
  North America              2486             546             1658
  South America              631              0               0
  Asia                       1026             0               279
  Africa                     254              0               0
  Australia                  63               0               0
  World                      0                0               448
  Europe and North America   217              651             580
  Europe and Australia       349              0               0

The percentage of men in trials about whom information was provided for various outcomes is shown in Table [3](#T3){ref-type="table"}. Reporting of efficacy was mixed. Almost all trials used the outcome of improved erections, and most used the final score or change from baseline in the erectile function domain of the IIEF. Also commonly reported was the percentage of attempts at sexual intercourse that were successful, usually as an average. Final scores on questions 3 and 4 of the IIEF, or change from baseline, were reported in over 90% of sildenafil trials, but in less than 30% of trials of tadalafil or vardenafil.

###### 

Percentage of men in all trials for whom an outcome is reported

  **Outcome**                   **Slidenafil n = 7077**   **Tadalafil n = 2036**   **Vardenafil n = 3274**
  ----------------------------- ------------------------- ------------------------ -------------------------
  **Efficacy**                                                                     
  Improved erections            83                        83                       100
  Mean \# erections/week        20                        0                        0
  Successful attempts at SI     47                        72                       100
  More than 60/75% successful   10                        0                        18
  More than 40% successful      0                         0                        0
  Final score IIEF Q3           94                        27                       26
  Mean change IIEF Q3           91                        27                       26
  Final score IIEF Q4           94                        27                       26
  Mean change IIEF Q4           91                        27                       26
  Final score EF Domain         56                        72                       100
  Mean change EF Domain         54                        83                       77
  Normal EF at endpoint         8                         56                       14
  **Withdrawals**                                                                  
  All-cause                     83                        65                       69
  Lack of efficacy              81                        72                       82
  Adverse event                 90                        83                       100
  **Adverse events**                                                               
  Men with any adverse event    42                        40                       18
  Severe                        27                        25                       35
  Serious                       38                        83                       78
  Treatment related             55                        3                        43
  Headache                      99                        90                       86
  Dyspepsia                     79                        71                       73
  Flushing                      99                        73                       73
  Nasal congestion/rhinitis     64                        35                       73
  Visual disturbances           89                        46                       55
  Back pain                     13                        73                       9
  Myalgia/increased CPK         16                        60                       18
  Flu syndrome                  17                        30                       34
  CV events                     24                        27                       33
  Limb pain                     10                        11                       0
  Fatigue                       3                         15                       0
  Priapism                      29                        0                        0
  Nausea                        14                        0                        0

Study withdrawal for any cause, or because of lack of efficacy or adverse events was commonly reported. The reporting of men with any adverse event, with severe or serious adverse events according to recognised adverse event reporting criteria, or those adverse events considered treatment related by investigators, was not consistent. Most studies reported specific adverse events only if they occurred in a certain proportion of men, usually between 2% and 5%. As a consequence, some adverse events (headache, dyspepsia, flushing, nasal congestion or rhinitis, or visual disturbance) were consistently reported while others were not.

Analysis
========

The first stage was a detailed analysis of outcomes for each intervention, followed by a comparison between interventions where there was sufficient information to make the comparison valid. To make comparisons between different interventions, similar outcomes and similar intensities of intervention have to be compared in similar patients. Only those outcomes with a reasonably high and consistent reporting frequency were available for comparison.

Individual analyses
-------------------

### Sildenafil

Results for continuous efficacy outcomes for sildenafil are shown in Table [4](#T4){ref-type="table"}. Average results for percentage successful attempts at intercourse, for the erectile function domain score, and for the change in the erectile function domain score from baseline were consistently available for the optimised dose, and for some trials with fixed dose. Combined data for 50 mg and 100 mg fixed doses and dose optimised regimens are reported (50/100).

###### 

Summary of continuous outcomes for sildenafil, tadalafil and vardenafil

  **Sildenafil**                                                              
  --------------------------------- ---------- --------------- -------------- -------------------
  Percentage successful attempts    placebo    16              1448           23
                                    50/100     16              1589           65
  Erectile function domain score    placebo    23              1870           14.0
                                    50/100     23              1893           22.0
  Erectile function domain change   placebo    23              1870           2.7
                                    50/100     23              1893           10.1
  **Tadalafil**                                                               
                                               **Number of**                  
                                                                              
  **Outcome**                       **Dose**   **Trials**      **Patients**   **Weighted mean**
                                                                              
  Percentage successful attempts    placebo    6               388            26
                                    10/20      6               1047           62
  Erectile function domain score    placebo    6               388            14.6
                                    10/20      6               1047           22.3
  Erectile function domain change   placebo    7               459            0.8
                                    10/20      7               1192           8.4
  **Vardenafil**                                                              
                                               **Number of**                  
                                                                              
  **Outcome**                       **Dose**   **Trials**      **Patients**   **Weighted mean**
                                                                              
  Percentage successful attempts    placebo    7               996            28
                                    10/20      7               1789           59
  Erectile function domain score    placebo    7               996            14.0
                                    10/20      7               1789           20.1
  Erectile function domain change   placebo    7               996            1.3
                                    10/20      7               1344           8.3

Results for dichotomous variables of efficacy and adverse events for sildenafil are shown in Table [5](#T5){ref-type="table"}. Here data were available for most studies. The analysis combined dose-optimised regimens with 100 mg fixed dose, since the bulk of patients on dose-optimised regimens were on 100 mg.

###### 

Summary of dichotomous outcomes for sildenafil

                                **Number of**   **Percent with**                                  
  -------------------- -------- --------------- ------------------ ----- ----- ------------------ ------------------------
  **Efficacy**                                                                                    
  Improved erections   25       5               778                68    27    2.5 (2.1 to 3.0)   2.4 (2.1 to 2.9)
                       50       5               781                80    27    3.0 (2.5 to 3.5)   1.9 (1.7 to 2.1)
                       100      26              5000               76    23    3.4 (3.1 to 3.6)   1.9 (1.8 to 2.0)
                       50/100   29              5467               76    23    3.3 (3.1 to 3.5)   1.9 (1.8 to 2.0)
                                                                                                  
  **Withdrawal**                                                                                  
  All-cause            25       3               522                11    14    0.9 (0.6 to 1.4)   not calculated
                       50       4               560                10    14    0.7 (0.4 to 1.2)   not calculated
                       100      27              5219               7.8   12    0.6 (0.5 to 0.8)   **22 (16 to 34)**
                       50/100   30              5562               8.0   12    0.7 (0.6 to 0.8)   **23 (17 to 37)**
  Lack of efficacy     25       3               522                3.0   3.7   0.9 (0.3 to 2.5)   not calculated
                       50       3               526                1.8   3.5   0.6 (0.2 to 1.9)   not calculated
                       100      27              5119               1.1   4.5   0.3 (0.2 to 0.4)   **24 (20 to 32)**
                       50/100   30              5463               1.2   4.4   0.3 (0.2 to 0.4)   **25 (21 to 34)**
  Adverse event        25       4               777                1.5   1.3   1.0 (0.4 to 3.0)   not calculated
                       50       5               819                1.6   1.2   1.7 (0.7 to 4.4)   not calculated
                       100      28              5311               1.4   0.6   1.8 (1.1 to 2.7)   ***120 (66 to 520)***
                       50/100   31              5787               1.6   0.6   1.7 (1.1 to 2.6)   ***120 (67 to 560)***
                                                                                                  
  **Adverse events**                                                                              
  All cause            50/100   18              2852               50    30    1.6 (1.5 to 1.8)   ***4.9 (4.2 to 6.0)***
  Serious              50/100   17              2591               2.5   2.4   1.1 (0.6 to 1.7)   not calculated
  Headache             50/100   34              6386               17    5.2   3.3 (2.8 to 3.9)   ***8.6 (7.6 to 10)***
  Dyspepsia            50/100   26              4967               7.8   2.3   3.3 (2.5 to 4.4)   ***18 (15 to 23)***
  Flushing             50/100   33              6363               13    1.9   6.7 (5.2 to 8.7)   ***9.0 (8.1 to 10)***
  Rhinitis             50/100   21              4283               5.4   2.1   2.5 (1.8 to 3.5)   ***31 (23 to 47)***

NNT is given in standard font, **NNTp in bold**, and ***NNH in bold italic***. No NNT/NNTp/NNH was calculated unless there was a statistically significant difference

For efficacy, the NNT for improved erections was the same at 1.9 for all doses above 25 mg, demonstrating comparable efficacy and justifying combining those doses. Combining all information on 50 mg and 100 mg with dose optimised regimens (5467 men), improved erections were reported in 76% of men on sildenafil and 23% on placebo (Figure [1](#F1){ref-type="fig"}). The NNT was 1.9 (95% confidence interval 1.8 to 2.0).

![Results of percentage of men with improved erections in individual trials of sildenafil, tadalafil, and vardenafil.](1471-2490-5-18-1){#F1}

Combining all information on 50 mg and 100 mg with dose optimised regimens, both all cause and lack of efficacy withdrawals reported in about 5600 men, were lower with sildenafil than with placebo, with NNTp values of 23 (17 to 37) and 25 (21 to 34) respectively. Adverse event withdrawals were higher with sildenafil than with placebo, with an NNH of 120 (67 to 560).

Combining all information on 50 mg and 100 mg with dose optimised regimens, particular adverse events were reported in 2600 to 6300 men, and were generally higher with sildenafil than with placebo, except serious adverse events, which were not different. NNH values varied between 4.9 (4.2 to 6.0) for men reporting at least one adverse event (49% of men taking sildenafil), to 18 (15 to 23) for men reporting dyspepsia. Headache was the most commonly reported individual adverse event in 17% of men taking sildenafil, followed by flushing reported in 13% and dyspepsia in 7.8%. The majority of trials reported that adverse events were mostly mild or moderate, and frequently transient.

### Tadalafil

Results for continuous efficacy outcomes for tadalafil are shown in Table [4](#T4){ref-type="table"}. Average results for percentage successful attempts at intercourse, for the erectile function domain score, and for the change in the erectile function domain score from baseline were consistently available for 20 mg fixed dose, but there were 109 men or fewer using 10 mg or less. Combined data for 10 mg and 20 mg fixed doses are reported (10/20).

Results for dichotomous variables of efficacy and adverse events are shown in Table [6](#T6){ref-type="table"}. For efficacy, the NNT for improved erections was 1.9 for both the 20 mg fixed dose and combined 10 plus 20 mg analysis. Combining all information on 10 mg and 20 mg, improved erections in 1651 men were reported in 75% of men on tadalafil and 24% on placebo (Figure [1](#F1){ref-type="fig"}). The NNT was 1.9 (95% confidence interval 1.8 to 2.1).

###### 

Summary of dichotomous outcomes for tadalafil

                               **Number of**   **Percent with**                                  
  -------------------- ------- --------------- ------------------ ----- ----- ------------------ ------------------------
  **Efficacy**                                                                                   
  Improved erections   10      2               215                64    23    2.8 (1.9 to 4.2)   2.4 (1.9 to 3.4)
                       20      7               1542               76    24    3.1 (2.7 to 3.7)   1.9 (1.7 to 2.1)
                       10/20   7               1651               75    24    3.1 (2.6 to 3.7)   1.9 (1.8 to 2.1)
                                                                                                 
  **Withdrawal**                                                                                 
  All-cause            10/20   5               1334               13    19    0.7 (0.5 to 0.9)   **15 (8.8 to 46)**
  Lack of efficacy     10/20   6               1435               3.3   7.5   0.5 (0.3 to 0.7)   **24 (14 to 69)**
  Adverse event        10/20   7               1657               3.4   1.5   2.3 (1.1 to 5.1)   ***52 (29 to 260)***
                                                                                                 
  **Adverse events**                                                                             
  All cause            10/20   3               590                47    25    1.8 (1.4 to 2.3)   ***4.6 (3.4 to 7.2)***
  Serious              10/20   7               1655               1.2   1.1   1.0 (0.4 to 2.8)   not calculated
  Headache             10/20   7               1810               13    3.4   3.5 (2.2 to 5.4)   ***11 (8.5 to 14)***
  Dyspepsia            10/20   6               1401               10    0.2   12 (4.3 to 35)     ***11 (8.8 to 14)***
  Flushing             10/20   6               1530               4.8   0.2   7.2 (2.5 to 20)    ***24 (18 to 38)***
  Rhinitis             10/20   2               712                3.1   0.5   4.5 (0.8 to 24)    not calculated

NNT is given in standard font, **NNTp in bold**, and ***NNH in bold italic***. No NNT/NNTp/NNH was calculated unless there was a statistically significant difference

Combining all information on 10 mg and 20 mg, both all cause and lack of efficacy withdrawals reported in about 1400 men, were lower with tadalafil than with placebo, with NNTp values of 15 (8.8 to 46) and 24 (14 to 69) respectively. Adverse event withdrawals were higher with tadalafil than with placebo, with an NNH of 52 (29 to 260).

Combining all information on 10 mg and 20 mg, particular adverse events were reported in 600 to 1800 men, and were generally higher with tadalafil than with placebo, except serious adverse events, which were not different, and rhinitis, where there were few events. NNH values varied between 4.6 (3.4 to 7.2) for men reporting at least one adverse event (47% of men taking tadalafil), to 24 (18 to 38) for men reporting dyspepsia. Headache was the most commonly reported individual adverse event in 13% of men taking tadalafil, followed by dyspepsia reported in 10% and flushing in 4.8%. The majority of trials reported that adverse events were mostly mild or moderate, and frequently transient.

### Vardenafil

Results for continuous efficacy outcomes for vardenafil are shown in Table [4](#T4){ref-type="table"}. Average results for percentage successful attempts at intercourse, for the erectile function domain score, and for the change in the erectile function domain score from baseline were consistently available for the optimised dose, and for some trials with fixed dose. Combined data for 10 mg and 20 mg fixed doses and dose optimised regimens are reported (10/20).

Results for dichotomous variables of efficacy and adverse events are shown in Table [7](#T7){ref-type="table"}. The analysis combined dose optimised regimens with the 20 mg fixed dose, since the bulk of patients on dose optimised regimens were taking 20 mg.

###### 

Summary of dichotomous outcomes for vardenafil

                               **Number of**   **Percent with**                                                
  -------------------- ------- --------------- ------------------ ----- ------------------- ------------------ ------------------------
  **Efficacy**                                                                                                 
  Improved erections   5       3               833                62    27                  2.3 (1.9 to 2.7)   2.9 (2.4 to 3.5)
                       10      5               1401               68    21                  3.3 (2.9 to 3.9)   2.1 (1.9 to 2.3)
                       20      7               2147               73    22                  3.4 (3.0 to 3.8)   2.0 (1.8 to 2.1)
                       10/20   7               2856               71    22                  3.3 (3.0 to 3.8)   2.0 (1.9 to 2.2)
                                                                                                               
  **Withdrawal**                                                                                               
  All-cause            10      3               812                4.2   2.5                 1.7 (0.8 to 3.7)   not calculated
                       20      5               1623               18    32                  0.6 (0.5 to 0.7)   **6.9 (5.4 to 9.7)**
                       10/20   5               2061               20    32                  0.6 (0.5 to 0.6)   **7.7 (6.0 to 11)**
  Lack of efficacy     5       2               505                11    18                  0.6 (0.4 to 0.9)   **14 (7.5 to 85)**
                       10      4               1084               4     15                  0.3 (0.2 to 0.4)   **9.3 (7.1 to 14)**
                       20      6               1831               4     13                  0.3 (0.2 to 0.4)   **11 (8.7 to 15)**
                       10/20   6               2320               4     12                  0.3 (0.2 to 0.4)   **11 (9.0 to 16)**
  Adverse event        5       3               812                4.2   2.5                 1.7 (0.8 to 3.7)   not calculated
                       10      5               1395               2.8   1.9                 1.5 (0.7 to 3.0)   not calculated
                       20      7               2161               3.6   1.8                 2.1 (1.2 to 5.3)   ***54 (31 to 210)***
                       10/20   7               2868               3.3   1.8                 1.8 (1.1 to 3.0)   ***65 (37 to 250)***
                                                                                                               
  **Adverse events**                                                                                           
  All cause            10/20                                            insufficient data                      
  Severe               10/20   3               1096               2.7   2.2                 1.2 (0.5 to 2.8)   not calculated
  Serious              10/20   5               1984               2.2   3.2                 0.7 (0.4 to 1.2)   not calculated
  Headache             10/20   6               2411               15    4.1                 3.4 (2.4 to 4.8)   ***9.6 (7.9 to 12)***
  Dyspepsia            10/20   5               1972               3.8   0.3                 7.3 (2.4 to 22)    ***31 (22 to 48)***
  Flushing             10/20   5               1984               13    0.8                 13 (6.3 to 27)     ***8.0 (6.9 to 9.6)***
  Rhinitis             10/20   5               2212               7.9   3.6                 2.2 (1.5 to 3.4)   ***23 (16 to 42)***

NNT is given in standard font, **NNTp in bold**, and ***NNH in bold italic***. No NNT/NNTp/NNH was calculated unless there was a statistically significant difference

For efficacy, the NNT for improved erections was the same at 2.0 for all doses above 5 mg, demonstrating comparable efficacy and justifying combining those doses. Combining all information on 10 mg and 20 mg with dose optimised regimens, improved erections in 2856 men were reported in 71% of men on vardenafil and 22% on placebo (Figure [1](#F1){ref-type="fig"}). The NNT was 2.0 (95% confidence interval 1.9 to 2.2).

Combining all information on 10 mg and 20 mg with dose optimised regimens, both all cause and lack of efficacy withdrawals reported in about 500 to 2300 men, were lower with vardenafil than with placebo, with NNTp values of 7.7 (6.0 to 11) and 11 (9.0 to 16) respectively. Adverse event withdrawals, reported in about 2800 men, were higher with vardenafil than with placebo, with an NNH of 65 (37 to 250).

Combining all information on 10 mg and 20 mg with dose optimised regimens, adverse event outcomes were reported in 1000 to 2400 men, and were generally higher with vardenafil than with placebo, except serious adverse events, which were not different, and men with at least one adverse event, which was not commonly reported in these trials. The lowest (worst) NNH was 8.0 (6.9 to 9.6) for men reporting flushing. Headache was the most commonly reported individual adverse event in 15% of men taking vardenafil, followed by flushing reported in 13% and rhinitis in 7.9%. The majority of trials reported that adverse events were mostly mild or moderate, and frequently transient.

Comparing different treatments
------------------------------

Continuous outcomes are compared in Table [8](#T8){ref-type="table"}, which documents the number of trials and patients for which the consistently reported outcomes were available, together with the weighted mean result for both placebo and the top doses plus dose optimised regimens of individual PDE-5 inhibitors. There was remarkable consistency. For instance, the percentage of successful attempts at intercourse with placebo varied narrowly between 23% and 28%. The three PDE-5 inhibitors had success rates of 65% for sildenafil, 62% for tadalafil and 59% for vardenafil (Figure [2](#F2){ref-type="fig"}). The final erectile function domain score, and change from baseline were highly consistent for both placebo and PDE-5 inhibitors.

###### 

Comparison of continuous efficacy results for sildenafil, tadalafil, and vardenafil

                                   **Sildenafil (50/100 mg)**   **Tadalafil (10/20 mg)**   **Vardenafil (10/20 mg)**                                                           
  -------------------------------- ---------------------------- -------------------------- --------------------------- ------ --------- --- ------ ------ --------- --- ------ ------
  Percentage successful attempts   placebo                      16                         1448                        23     placebo   6   388    26     placebo   7   996    28
                                   50/100                       16                         1589                        65     10/20     6   1047   62     10/20     7   1789   59
                                                                                                                                                                               
  Erectile function domain score   placebo                      23                         1870                        14.0   placebo   6   388    14.6   placebo   7   996    14.0
                                   50/100                       23                         1893                        22.0   10/20     6   1047   22.3   10/20     7   1789   20.1
                                                                                                                                                                               
  EF domain change                 placebo                      23                         1870                        2.7    placebo   7   459    0.8    placebo   7   996    1.3
                                   50/100                       23                         1893                        10.1   10/20     7   1192   8.4    10/20     7   1344   8.3

![Summary of percentage of successful attempts at intercourse (Successful), percentage of men with improved erections (Improved), and of all-cause withdrawals (Withdrawals) for top doses of sildenafil, tadalafil and vardenafil.](1471-2490-5-18-2){#F2}

Dichotomous outcomes are compared in Table [9](#T9){ref-type="table"}, documenting the number of trials and patients for which the consistently reported outcomes were available, together with event rates for PDE-5 inhibitor and placebo, and the NNT/NNTp/NNH values obtained. For efficacy, using improved erections as the outcome, there was a high degree of consistency for placebo with rates between 22% and 24%. The three PDE-5 inhibitors had event rates of 76% for sildenafil, 75% for tadalafil and 71% for vardenafil (Figure [2](#F2){ref-type="fig"}). NNTs for all three PDE-5 inhibitors were 1.9 or 2.0.

###### 

Comparison of dichotomous efficacy results for sildenafil, tadalafil, and vardenafil

                       **Sildenafil (50/100 mg)**   **Tadalafil (10/20 mg)**   **Vardenafil (10/20 mg)**                                                                                                                         
  -------------------- ---------------------------- -------------------------- --------------------------- ----- ------------------------ --- ------ ----- ----- ------------------------ ------------------- ------ ----- ----- ------------------------
  **Efficacy**                                                                                                                                                                                                                   
  Improved erections   29                           5467                       76                          23    1.9 (1.8 to 2.0)         7   1651   75    24    1.9 (1.8 to 2.1)         7                   2856   71    22    2.0 (1.9 to 2.2)
                                                                                                                                                                                                                                 
  **Withdrawal**                                                                                                                                                                                                                 
  All-cause            30                           5562                       8                           12    **23 (17 to 37)**        5   1334   13    19    **15 (8.8 to 46)**       5                   2061   20    32    **7.7 (6.0 to 11)**
  Lack of efficacy     30                           5463                       1.2                         4.4   **25 (21 to 34)**        6   1435   3.3   7.5   **24 (14 to 69)**        6                   2320   4.0   12    **11 (9.0 to 16)**
  Adverse event        31                           5787                       1.6                         0.6   ***120 (67 to 560)***    7   1657   3.4   1.5   ***52 (29 to 260)***     7                   2868   3.3   1.8   ***65 (37 to 250)***
                                                                                                                                                                                                                                 
  **Adverse events**                                                                                                                                                                                                             
  All cause            18                           2862                       50                          30    ***4.9 (4.2 to 6.0)***   3   590    47    25    ***4.6 (3.4 to 7.2)***   insufficient data                      
  Serious              17                           2591                       2.5                         2.4   not calculated           7   1655   1.2   1.1   not calculated           5                   1984   2.2   3.2   not calculated
  Headache             34                           6386                       17                          5.2   ***8.6 (7.6 to 10)***    7   1810   13    3.4   ***11 (8.5 to 14)***     6                   2411   15    4.1   ***9.6 (7.9 to 12)***
  Dyspepsia            26                           4967                       7.8                         2.3   ***18 (15 to 23)***      6   1401   10    0.2   ***11 (8.8 to 14)***     5                   1972   3.8   0.3   ***31 (22 to 48)***
  Flushing             33                           6363                       13                          1.9   ***9.0 (8.1 to 10)***    6   1530   4.8   0.2   ***24 (18 to 38)***      5                   1984   13    0.8   ***8.0 (6.9 to 9.6)***
  Rhinitis             21                           4283                       5.4                         2.1   ***31 (23 to 47)***      2   712    3.1   0.5   not calculated           5                   2212   7.9   3.6   ***23 (16 to 42)***

NNT is given in standard font, **NNTp in bold**, and ***NNH in bold italic***. No NNT/NNTp/NNH was calculated unless there was a statistically significant difference

There was much less consistency for information on withdrawals. For instance, all cause and lack of efficacy withdrawals were considerably higher with placebo in vardenafil trials (32% and 12%) than with sildenafil trials (12% and 4.4%), with tadalafil intermediate between them. A similar gradient occurred for all cause (Figure [2](#F2){ref-type="fig"}) and lack of efficacy withdrawals with PDE-5 inhibitors, resulting in lower (better) NNTp values with vardenafil and tadalafil than sildenafil because of these higher absolute rates. Adverse event withdrawals were actually lower with sildenafil than with tadalafil or vardenafil.

Event rates for particular adverse events tended to be consistent between the PDE-5 inhibitor studies, with minor differences. About half the men reported at least one adverse event, though serious adverse events never occurred more frequently with PDE-5 inhibitor than with placebo. Headache was consistently the most commonly reported individual adverse event. Flushing, dyspepsia, or rhinitis/nasal congestion were also common, though with different rates occurring with different PDE-5 inhibitors.

Other adverse events
--------------------

Other adverse events were reported inconsistently. Back pain and myalgia or increased CPK levels were mentioned consistently in tadalafil studies, but neither of the other PDE-5 inhibitors (Table [3](#T3){ref-type="table"}). Other adverse events (\'flu syndrome, limb pain, CV events, fatigue, priapism, and nausea) were reported on in only a small minority of men in trials. Whether visual disturbances occurred was recorded for a large proportion of men, but not in consistent terms, limiting the ability to pool data. Most studies reported that visual disturbances were uncommon.

Relationship between dosing and intercourse
-------------------------------------------

There was generally no information on intervals between dosing and timing of intercourse, either for speed of onset of effect or duration of effect. Table [10](#T10){ref-type="table"} shows the only consistent information concerning timing of intercourse, from four studies \[[@B58],[@B59],[@B61],[@B63]\] comparing tadalafil 20 mg with placebo. The majority of attempts and successful attempts occurred within four hours, and about 90% within 12 hours. Success rates with tadalafil 20 mg and placebo did not differ, whatever time intercourse occurred. No other studies provided useful information relating to timing of intercourse after dosing.

###### 

Relationship of dosing to time and success of intercourse for tadalafil 20 mg and placebo in four trials

                                                      **Time after dose (hours)**              
  --------------------------------------------------- ----------------------------- ---- ----- -----
  **Percent of total attempts at intercourse**                                                 
  Placebo                                             75                            15   9.0   1.7
  Tadalafil 20 mg                                     61                            23   12    3.7
                                                                                               
  **Percent of successful attempts at intercourse**                                            
  Placebo                                             74                            15   8.4   3.3
  Tadalafil 20 mg                                     60                            23   13    4
                                                                                               
  **Percent of attempts that were successful**                                                 
  Placebo                                             26                            26   24    50
  Tadalafil 20 mg                                     65                            68   72    74

Discussion
==========

This analysis comprised 50 randomised comparisons of PDE-5 inhibitors with placebo, in more than 12,000 men. Trials included were all randomised and double blind, and almost all (47/50) were of sufficiently high quality (score of 3 or more out of 5) to avoid major known sources of bias \[[@B73]\].

There was no direct comparison between one PDE-5 inhibitor and another that satisfied our inclusion criteria. Three studies did make a direct comparison between sildenafil and tadalafil, with no placebo. They are not included in the analysis because one \[[@B74]\] was open, another \[[@B75]\] was not convincingly double-blind, and the third \[[@B76]\] used only four tablets per patient. All three studies looked at duration of effect, and two looked at patient preferences. In these less than adequate trials, both drugs seem to be equally effective up to 12 hours after dosing, and both drugs were well tolerated.

Published reports of three PDE-5 inhibitors for treatment of male erectile dysfunction, while largely similar, had interesting differences. These were principally in the underlying aetiology of erectile dysfunction, regions of the world where studies were performed, and in exclusion criteria used to select men for the individual trials. Sildenafil was studied in 10 different clinical conditions, compared with only three for tadalafil and vardenafil (Table [1](#T1){ref-type="table"}). The only condition missing for sildenafil was after prostatectomy, where studies could not be included because they were not randomised. Most studies were performed in North America and Europe (Table [2](#T2){ref-type="table"}), though sildenafil was studied in men in every inhabited continent, with 27% of men studied being in Asia, South America, or Africa.

Perhaps the most obvious difference between trials of different drugs was the use of different exclusion criteria in individual studies. Five of eight tadalafil studies, and six of seven vardenafil studies excluded men previously unresponsive to PDE-5 inhibitors, thus permitting enrolment to be enriched by responders compared with sildenafil studies, in which such an exclusion would not have been used because it was the first available PDE-5 inhibitor. It is not clear how this major difference might have affected the measured performance of the drugs. Exclusion of non-responders to other PDE-5 inhibitors might be expected to enhance the measured performance of any other PDE-5 inhibitor under test, making it look better in indirect comparisons. However, one vardenafil study including men previously unresponsive to sildenafil \[[@B70]\] was not greatly different from those overall.

The other major difference was in the reporting of outcomes of studies, which varied greatly between the three PDE-5 inhibitors. Common outcomes were responses to a global question about improved erections (\"Has the treatment you have been taking over the past four weeks improved your erections?\"), and scores and change in score for the erectile function domain. Some outcomes were frequently reported in trials of one treatment, but not others. For example, final scores and changes from baseline for IIEF questions 3 and 4, were reported for most sildenafil, but not tadalafil or vardenafil trials.

There were clear differences in the philosophy of reporting of efficacy and harm, principally between the first PDE-5 inhibitor sildenafil, and the subsequent ones, tadalafil and vardenafil (Table [3](#T3){ref-type="table"}). We could find no explanation for this, nor any philosophical discussion about the clinical and practical importance of different outcomes. Few studies provided an estimate of how many men had an outcome approximating erections sufficiently rigid for penetration followed by successful intercourse. This simple pragmatic outcome is more relevant to affected men, their partners, and their professional advisers than an average movement on a scale like IIEF, which itself comprises a number of different questions. Useful outcomes, like the number of men in whom the proportion of successful attempts at sexual intercourse was more than 40%, or 60% or more, known to be recorded in clinical trial reports for sildenafil \[[@B6]\], were almost never reported in published papers. Incomplete reporting of efficacy outcomes has been reported before, for chronic \[[@B4]\] and acute \[[@B77]\] pain.

Withdrawal from studies for any cause, because of lack of effect, or because of adverse events was commonly reported, while numbers of men with at least one adverse event and occurrence of severe adverse events, was recorded for a minority of trials. Serious adverse events were recorded more frequently in tadalafil and vardenafil trials than sildenafil trials, perhaps reflecting recency of studies. The use of a cut-off level for reporting individual adverse events limited the available information for these outcomes.

Analysis of the individual PDE-5 inhibitors (Tables [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}, [6](#T6){ref-type="table"}, [7](#T7){ref-type="table"}) showed that the two top doses (including dose-optimisation schedules) had very similar efficacy for all three interventions. This consistency justified pooling information from the two top doses.

Using this strategy to compare the three PDE-5 inhibitors demonstrated remarkable consistency between them on the basis of available data for any commonly reported outcome. Absolute rates for placebo varied little, showing no major difference between patients studied. The only exception to this was for withdrawals, where tadalafil and vardenafil studies had higher withdrawal rates with placebo and PDE-5 inhibitor than did sildenafil. There was no obvious reason for this. It was perhaps surprising that sildenafil compared well with tadalafil and vardenafil given the much greater number of conditions studied, the wider geographical spread, and that tadalafil and vardenafil studies used a form of enriched enrolment. Overall, sildenafil offered most information, and a trend towards better efficacy and lower adverse events.

How useful is this method of indirect comparison of equivalent doses of PDE-5 inhibitors? It is clearly superior to examining the little inadequate information on direct comparison, and to any superficial examination of individual trials, subject, as each will be, to the random play of chance \[[@B13]\]. Large collections of data from high quality, valid, trials are less subject to the vagaries of chance than smaller individual studies. Large direct comparisons may be better, but the evidence is that when large amounts of trial data exist, direct comparisons give no different result from indirect comparisons \[[@B1]\]. Further investigation of differences between comparable doses would require access to detailed clinical trial reports to report outcomes available but not published.

More important than direct or indirect comparison of different PDE-5 inhibitors is the question of utility of outcomes. With over 12,000 men in clinical trials over a decade, it is surprising that we have no consensus of what is a useful outcome, and how a useful outcome is reported. Individual patient analysis of clinical trial data illustrates how standard trials could be better reported \[[@B6],[@B77]\], and this has already been done for PDE-5 inhibitors \[[@B6]\].
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